Trials / Completed
CompletedNCT05281523
Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2)
A Randomised, Double-blind, Parallel Group Phase III Study to Assess the Efficacy and Safety of 100 mg SC Depemokimab in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) - ANCHOR-2 (depemokimAb iN CHrOnic Rhinosinusitis)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 264 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and safety of depemokimab (GSK3511294) in participants with Chronic rhinosinusitis with nasal polyps (CRSwNP).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Depemokimab (GSK3511294) | Depemokimab (GSK3511294) was administered using a pre-filled syringe. |
| DRUG | Placebo | Placebo was administered as normal saline using a pre-filled syringe. |
Timeline
- Start date
- 2022-04-18
- Primary completion
- 2024-07-12
- Completion
- 2024-08-06
- First posted
- 2022-03-16
- Last updated
- 2025-09-09
- Results posted
- 2025-09-09
Locations
84 sites across 9 countries: United States, China, Italy, Japan, Poland, Romania, Spain, Sweden, Turkey (Türkiye)
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05281523. Inclusion in this directory is not an endorsement.